WADA, Sports, and Peptides: The Complete Anti-Doping Guide

The World Anti-Doping Agency (WADA) maintains a comprehensive Prohibited List identifying peptides and peptide analogs prohibited in competition. Prohibited peptide categories include: (1) Growth hormone and its analogs/mimetics (somatropin/somatotropin and synthetic variants), (2) Growth hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin), (3) Growth hormone-releasing hormones (GHRH and analogs), (4) Insulin-like growth factor-1 (IGF-1) and analogs, (5) Mechano growth factors, (6) Myostatin inhibitors, and (7) Erythropoietin and analogs. This broad categorization captures dozens of specific compounds used in sports doping, though WADA's list is not exhaustive—new peptides are continually synthesized and evaluated for anti-doping status. The guiding principle is that peptides with anabolic, performance-enhancing, or masking effects fall under anti-doping prohibition.

Growth hormone secretagogues (GH-releasing peptides) represent a particularly contentious category because numerous compounds have legitimate therapeutic applications while also possessing performance-enhancing effects relevant to sports. Compounds like CJC-1295, sermorelin, GHRP-2, and ipamorelin are prescribed in clinical medicine for growth hormone deficiency yet are WADA-prohibited due to their performance-enhancing potential in sports contexts. BPC-157 and TB-500, while not explicitly listed on the WADA prohibited list as of 2025, remain under regulatory scrutiny because their wound healing and anti-inflammatory properties theoretically provide competitive advantages in recovery from training stress. The absence of explicit prohibition does not necessarily indicate anti-doping approval; WADA maintains authority to expand prohibitions when evidence suggests performance-enhancing potential. Consequently, athletes must navigate regulatory uncertainty regarding compounds not explicitly listed but potentially subject to future prohibition.

Growth hormone secretagogues—peptides that stimulate endogenous growth hormone release—represent perhaps the most sought-after peptide category in sports doping because GH provides multiple performance-enhancing effects: increased muscle protein synthesis, enhanced recovery from training, improved bone density, and fat reduction. Clinically approved GH therapy for growth hormone deficiency is legal and appropriate; however, supraphysiologic GH administration in eugonadal (normal-GH-producing) athletes confers competitive advantages and is anti-doping prohibited. GH secretagogues (CJC-1295, sermorelin, GHRP analogs) provide indirect GH elevation through endogenous stimulation, making GH doping detection challenging. Athletes using GH secretagogues can theoretically achieve performance-enhancing GH elevation while avoiding direct exogenous GH detection—a loophole in anti-doping systems that has driven secretagogue use in elite sports.

The performance-enhancing effects of GH secretagogues are substantial and well-documented. Endurance athletes benefit from improved oxygen utilization and mitochondrial function. Strength athletes gain muscle hypertrophy, strength improvements, and recovery acceleration. Aesthetic athletes (bodybuilding, physique) pursue fat reduction and muscularity optimization. The breadth of athletic applications has made GH secretagogues popular across diverse sports despite explicit WADA prohibition. WADA's recognition of this threat has driven development of detection methods and repeated administrative reinforcement of secretagogue prohibition. However, athletes continue attempting to circumvent detection through microdeleting secretagogue administration, timing usage to minimize detection window, and exploiting detection gaps. The arms race between doping innovation and detection technology continues with GH secretagogues at the center.

WADA detection of peptide doping employs multiple analytical approaches reflecting peptide chemistry and metabolism differences from traditional small-molecule performance-enhancing drugs. The most sophisticated methods include the Athlete Biological Passport (ABP), which monitors biological markers of GH administration (IGF-1, procollagen ratios, testosterone/epitestosterone ratios, hemoglobin) over time to detect performance-enhancing substance use indirectly. Direct peptide detection uses high-performance liquid chromatography (HPLC) and mass spectrometry to identify specific peptides in urine samples. However, most peptides are rapidly metabolized, creating short detection windows (24-48 hours) that athletes exploit through timing administration after competition.

Technical limitations in peptide detection create genuine challenges for anti-doping enforcement. Many peptides are structurally similar to endogenously produced compounds (e.g., exogenous GH is chemically identical to endogenous GH), requiring sophisticated isotope ratio mass spectrometry to detect the small differences between exogenous and endogenous sources. Peptide detection sensitivity has improved substantially since 2010 through technological advances, but gaps persist. Detection windows for many peptides remain short (24-72 hours) compared to detection windows for small-molecule drugs (weeks to months), creating incentive for athletes to exploit the limited detection window through careful administration timing. WADA continues investing in improved detection methods, but technological limitations mean that some peptide doping remains undetectable with current methods. This reality has influenced WADA policy toward stricter procedural oversight (biological passport development, targeted testing) rather than relying exclusively on direct peptide detection.

High-profile athlete cases involving peptide doping have shaped anti-doping enforcement patterns and public understanding of peptide performance-enhancing effects. The 2008 case of balco (Bay Area Laboratory Cooperative) scandal revealed systematic GH doping in baseball, track and field, and football, demonstrating that elite athletes across sports pursued performance-enhancing peptide doping. Subsequent cases involving major track athletes (Tyson Gay, Asafa Powell) and cyclists revealed secretagogue usage (CJC-1295, GHRP) in endurance sports. These cases generated substantial anti-doping focus on peptide detection and enforcement. WADA has pursued notable sanctions against violators, including lifetime bans for repeat offenders and substantial competitive suspensions for first-time violators.

The enforcement landscape has become increasingly sophisticated, with testing protocols expanded to capture GH secretagogue use through both direct detection and biological passport monitoring. Notable cases since 2020 have involved athletes appealing anti-doping sanctions based on contaminated supplements or therapeutic use exemption claims. Several athletes have successfully challenged anti-doping determinations based on insufficient detection methodology or procedural violations, highlighting remaining gaps in anti-doping enforcement systems. The visibility of notable cases has increased public awareness of peptide doping while simultaneously creating perception (among athletes and coaches) that anti-doping authorities face detection limitations, perpetuating doping despite enforcement efforts. The competitive arms race between anti-doping innovation and athlete doping sophistication continues with peptides remaining central to the conflict.

BPC-157 and TB-500, while not explicitly listed on the WADA Prohibited List, exist in anti-doping regulatory gray zones where their status remains technically uncertain. Both peptides demonstrate wound healing, anti-inflammatory, and recovery-enhancing properties that confer potential competitive advantage in sports where training stress recovery is performance-limiting. Athletes in combat sports, weightlifting, and endurance athletics have pursued BPC-157 and TB-500 for purported recovery benefits. However, WADA has not formally prohibited these compounds, creating ambiguity regarding legality in competition. Some athletes interpret the absence of explicit prohibition as anti-doping approval; others recognize potential future prohibition and avoid use to minimize sanctions risk.

The regulatory uncertainty reflects several factors: limited evidence of systemic abuse in elite sports, mechanistic uncertainty regarding whether recovery benefits constitute prohibited performance enhancement, and WADA's general prohibition philosophy focusing on compounds with clearly established performance-enhancing effects. However, the recent FDA actions designating BPC-157 and TB-500 as Category 2 bulk drug substances have indirectly influenced anti-doping discussions by establishing regulatory authority determinations that these compounds warrant restricted status in medical contexts. Whether WADA will eventually formally prohibit BPC-157 and TB-500 remains open, but the trajectory suggests increasing likelihood given growing evidence of competitive advantage potential and regulatory trends toward enhanced restriction. Athletes using these compounds should anticipate potential future prohibition and consequent sanctions.

Selective androgen receptor modulators (SARMs) and peptides frequently appear together in athlete doping regimens, representing complementary performance-enhancing strategies. SARMs provide direct anabolic effects (muscle hypertrophy, strength) while peptides provide GH stimulation and recovery enhancement. The combination of SARMs and GH secretagogues creates synergistic performance-enhancing effects exceeding either agent alone. Anti-doping enforcement has identified athlete cases involving concurrent SARMs and peptide use, suggesting athletes strategically combine compounds to optimize performance enhancement while attempting to evade detection. WADA's prohibition of both SARMs and peptides reflects recognition that both compound classes contribute to prohibited performance enhancement.

The practical reality is that athlete doping with peptides typically occurs in context of broader doping regimens including SARMs, anabolic steroids, and other performance-enhancing agents. Consequently, anti-doping enforcement targeting one compound class (e.g., peptide-specific testing) captures limited total doping activity. More comprehensive anti-doping effectiveness requires systematic testing of all prohibited compound classes and sophisticated biological monitoring detecting patterns of performance-enhancing substance use rather than relying on single-compound detection. This systematic approach has become increasingly standard in anti-doping enforcement, though resource limitations and technical constraints continue limiting detection completeness.

Athletes with legitimate medical indications for peptide therapy (e.g., growth hormone deficiency, thyroid disorders) can obtain Therapeutic Use Exemptions (TUEs) from WADA permitting otherwise-prohibited compound use under medical supervision. TUE applications require documentation of medical diagnosis, evidence of therapeutic necessity, and certification that no alternative permitted therapy exists. Approved TUEs grant conditional anti-doping exemptions specific to the approved compound, dose, and medical indication. However, TUE approval has become increasingly restrictive, with WADA skeptical of claims that elite athletes suffer from conditions (growth hormone deficiency, adrenal insufficiency) requiring peptide therapy. The skepticism reflects realistic concern that athletes manipulate medical diagnoses or therapeutically dose supra-therapeutic quantities while claiming TUE protection.

TUE requirements create practical barriers for athletes with genuine medical peptide indications: obtaining approval requires substantial medical documentation, anti-doping authority review, and often multiple applications and appeals. Some elite athletes have successfully obtained TUEs for growth hormone deficiency and subsequent somatropin therapy, but the approval rate has declined as anti-doping authorities have become more restrictive. The consequence is that athletes with medical indications may face choices between untreated medical conditions and anti-doping violation risk. This tension between legitimate therapeutic access and anti-doping prohibition reflects fundamental policy challenges in balancing athlete safety/medical care against anti-doping integrity.